论文部分内容阅读
[目的]评价适形放疗同步紫杉醇、顺铂方案治疗D2术后胃癌的临床疗效和毒副反应。[方法]采用三维适形放疗(3D-CRT)技术DT60Gy和紫杉醇135mg/m2,d1、d29,DDP20mg/m2,d1～3、d29～31同步化疗。[结果]2年生存率、2年无复发生存率分别为88.4%、68.7%。治疗相关毒性反应总体较轻,患者耐受好,1例患者出现治疗相关死亡。30.3%(10/33)患者治疗失败。[结论]胃癌D2术后的同步放化疗方案效果较好。适形放疗技术的应用可减轻放疗相关毒性反应,尤其是血液学和胃肠道反应。
[Objective] To evaluate the clinical efficacy and side effects of concomitant radiotherapy combined with paclitaxel and cisplatin in the treatment of D2 gastric cancer. [Methods] Three-dimensional conformal radiotherapy (3D-CRT) DT60Gy and paclitaxel 135mg / m2, d1, d29, DDP20mg / m2, d1-3, d29-31 synchronous chemotherapy. [Results] The 2-year survival rate and 2-year recurrence-free survival rate were 88.4% and 68.7% respectively. Treatment-related toxicities were generally mild with well-tolerated patients and 1 patient had treatment-related deaths. 30.3% (10/33) patients failed treatment. [Conclusion] The concurrent chemoradiotherapy after D2 surgery of gastric cancer is better. The use of conformal radiotherapy can reduce radiation-related toxicities, especially hematology and gastrointestinal reactions.